MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.
The Company will receive significant exposure through millions of content brand insertions on the AGORACOM network and extensive search engine marketing over the next 12 months. In addition, exclusive sponsorships of invaluable digital properties such as AGORACOM TV, the AGORACOM home page and the AGORACOM Twitter account will serve to significantly raise the brand awareness of the Company among small cap investors.
SHARES FOR SERVICES PROGRAM
The Company has obtained acceptance in principle to the Agreement with AGORACOM pursuant to which it intends to issue shares for services to AGORACOM in exchange for the online advertising, marketing and branding services (“Advertising Services”). Pursuant to the terms of the Agreement, and subject to all relevant regulatory and other consents and approvals, including, but not limited to, acceptance from the TSX-V, the company will be issuing;
• $12,000 + HST in shares for services upon commencement, May 11, 2020, for prior preparation;
• $12,000 + HST in shares for Advertising Services at end of Third Month – August 11, 2020;
• $12,000 + HST in shares for Advertising Services at end of Sixth Month – November 11, 2020;
• $12,000 + HST in shares for Advertising Services at end of Ninth Month – February 11, 2021;
• $12,000 + HST in shares for Advertising Services at end of Twelfth Month – May 30, 2021.
The number of shares to be issued in respect of each period will be determined by using the undiscounted closing price of the Shares of the Company on the TSX Venture Exchange on the last trading day before the issuance of the news release announcing each issuance of shares once the services have been performed by AGORACOM.
The term of the Agreement is for 12 months effective immediately. The Company will issue a press release after the issuance of shares under the terms of the agreement.
SIGNIFICANT EXPOSURE THROUGH AGORACOM DIGITAL NETWORK
In 2019, AGORACOM surpassed 600 million page views, exceeded industry engagement metrics by over 400% and has served over 350 public companies.
The MedX HUB containing multiple landing pages, videos, photos and other helpful information updated in real-time over the next 12 months can be found at https://agoracom.com/ir/MDX.
The MedX HUB will receive significant exposure through continuous brand impression, content marketing, search engine marketing and social media engagement throughout the entire AGORACOM network. AGORACOM is the only small cap marketing firm to hold a Twitter Verified badge, averaging 4.2 million Twitter impressions per month in 2019.
MODERATED DISCUSSION FOR MEDX MANAGEMENT AND SHAREHOLDERS
MedX has also launched “CEO Verified” Discussion Forum on AGORACOM to serve as the Company’s primary social media platform to interact with both current and prospective shareholders in a fully moderated environment.
AGORACOM “CEO Verified” forums provide the small cap industry’s first ever identity verification of company executives on an investor platform. For the first time ever, small cap CEO’s and officers can post within a discussion forum without the risk of impersonation. As the ultimate influencers of their own companies, “CEO Verified” Forums create unmatched levels of engagement between management and investors that create civilized, constructive and factual conversation.
The MedX Forum can be found at https://agoracom.com/ir/MDX/forums/discussion
VERIFIED MEDX OFFICER AT LAUNCH
- Mike Druhan, VP Corporate Development
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.